

AMENDMENTS TO LB 670

Introduced by Schilz

1 1. Strike the original sections and all amendments
2 thereto and insert the following new sections:

3 Section 1. Section 28-405, Revised Statutes Supplement,
4 2011, is amended to read:

5 28-405 The following are the schedules of controlled
6 substances referred to in the Uniform Controlled Substances Act:

7 Schedule I

8 (a) Any of the following opiates, including their
9 isomers, esters, ethers, salts, and salts of isomers, esters, and
10 ethers, unless specifically excepted, whenever the existence of
11 such isomers, esters, ethers, and salts is possible within the
12 specific chemical designation:

13 (1) Acetylmethadol;

14 (2) Allylprodine;

15 (3) Alphacetylmethadol, except levo-alphacetylmethadol
16 which is also known as levo-alpha-acetylmethadol, levomethadyl
17 acetate, and LAAM;

18 (4) Alphameprodine;

19 (5) Alphamethadol;

20 (6) Benzethidine;

21 (7) Betacetylmethadol;

22 (8) Betameprodine;

23 (9) Betamethadol;

- 1 (10) Betaprodine;
- 2 (11) Clonitazene;
- 3 (12) Dextromoramide;
- 4 (13) Difenoquin;
- 5 (14) Diampromide;
- 6 (15) Diethylthiambutene;
- 7 (16) Dimenoxadol;
- 8 (17) Dimepheptanol;
- 9 (18) Dimethylthiambutene;
- 10 (19) Dioxaphetyl butyrate;
- 11 (20) Dipipanone;
- 12 (21) Ethylmethylthiambutene;
- 13 (22) Etonitazene;
- 14 (23) Etozeridine;
- 15 (24) Furethidine;
- 16 (25) Hydroxypethidine;
- 17 (26) Ketobemidone;
- 18 (27) Levomoramide;
- 19 (28) Levophenacymorphan;
- 20 (29) Morpheridine;
- 21 (30) Noracymethadol;
- 22 (31) Norlevorphanol;
- 23 (32) Normethadone;
- 24 (33) Norpipanone;
- 25 (34) Phenadoxone;
- 26 (35) Phenampromide;
- 27 (36) Phenomorphan;

- 1 (37) Phenoperidine;
- 2 (38) Piritramide;
- 3 (39) Proheptazine;
- 4 (40) Properidine;
- 5 (41) Propiram;
- 6 (42) Racemoramide;
- 7 (43) Trimeperidine;
- 8 (44) Alpha-methylfentanyl,
9 N-(1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl) propionanilide,
10 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine;
- 11 (45) Tilidine;
- 12 (46) 3-Methylfentanyl,
13 N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-phenylpropanamide, its
14 optical and geometric isomers, salts, and salts of isomers;
- 15 (47) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its
16 optical isomers, salts, and salts of isomers;
- 17 (48) PEPAP, 1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine,
18 its optical isomers, salts, and salts of isomers;
- 19 (49) Acetyl-alpha-methylfentanyl,
20 N-(1-(1-methyl-2-phenethyl)-4-piperidinyl)-N-phenylacetamide, its
21 optical isomers, salts, and salts of isomers;
- 22 (50) Alpha-methylthiofentanyl,
23 N-(1-methyl-2-(2-thienyl)ethyl-4-piperidinyl)-N-phenylpropanamide,
24 its optical isomers, salts, and salts of isomers;
- 25 (51) Benzylfentanyl,
26 N-(1-benzyl-4-piperidyl)-N-phenylpropanamide, its optical
27 isomers, salts, and salts of isomers;

- 1 (6) Cyprenorphine;
 - 2 (7) Desomorphine;
 - 3 (8) Dihydromorphine;
 - 4 (9) Drotebanol;
 - 5 (10) Etorphine, except hydrochloride salt;
 - 6 (11) Heroin;
 - 7 (12) Hydromorphenol;
 - 8 (13) Methyldesorphine;
 - 9 (14) Methyldihydromorphine;
 - 10 (15) Morphine methylbromide;
 - 11 (16) Morphine methylsulfonate;
 - 12 (17) Morphine-N-Oxide;
 - 13 (18) Myrophine;
 - 14 (19) Nicocodeine;
 - 15 (20) Nicomorphine;
 - 16 (21) Normorphine;
 - 17 (22) Pholcodine; and
 - 18 (23) Thebacon.
- 19 (c) Any material, compound, mixture, or preparation which
20 contains any quantity of the following hallucinogenic substances,
21 their salts, isomers, and salts of isomers, unless specifically
22 excepted, whenever the existence of such salts, isomers, and salts
23 of isomers is possible within the specific chemical designation,
24 and, for purposes of this subdivision only, isomer shall include
25 the optical, position, and geometric isomers:
- 26 (1) Bufotenine. Trade and other names shall include, but
27 are not limited to: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole;

1 3-(2-dimethylaminoethyl)-5-indolol; N,N-dimethylserotonin;
2 5-hydroxy-N,N-dimethyltryptamine; and mappine;
3 (2) Diethyltryptamine. Trade and other names shall
4 include, but are not limited to: N,N-Diethyltryptamine; and DET;
5 (3) Dimethyltryptamine. Trade and other names shall
6 include, but are not limited to: DMT;
7 (4) 4-bromo-2,5-dimethoxyamphetamine. Trade
8 and other names shall include, but are not limited
9 to: 4-bromo-2,5-dimethoxy-alpha-methylphenethylamine; and
10 4-bromo-2,5-DMA;
11 (5) 4-methoxyamphetamine. Trade and other
12 names shall include, but are not limited to:
13 4-methoxy-alpha-methylphenethylamine; and paramethoxyamphetamine,
14 PMA;
15 (6) 4-methyl-2,5-dimethoxyamphetamine. Trade and
16 other names shall include, but are not limited to:
17 4-methyl-2,5-dimethoxy-alpha-methylphenethylamine; DOM; and STP;
18 (7) 5-methoxy-N,N-dimethyltryptamine;
19 (8) Ibogaine. Trade and other names
20 shall include, but are not limited to:
21 7-Ethyl-6,6beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido
22 (1',2':1,2) azepino (5,4-b) indole; and Tabernanthe iboga;
23 (9) Lysergic acid diethylamide;
24 (10) Marijuana;
25 (11) Mescaline;
26 (12) Peyote. Peyote shall mean all parts of the plant
27 presently classified botanically as *Lophophora williamsii* Lemaire,

1 whether growing or not, the seeds thereof, any extract from
2 any part of such plant, and every compound, manufacture, salts,
3 derivative, mixture, or preparation of such plant or its seeds or
4 extracts;

5 (13) Psilocybin;

6 (14) Psilocyn;

7 (15) Tetrahydrocannabinols, including, but not limited
8 to, synthetic equivalents of the substances contained in the plant
9 or in the resinous extractives of cannabis, sp. or synthetic
10 substances, derivatives, and their isomers with similar chemical
11 structure and pharmacological activity such as the following: Delta
12 1 cis or trans tetrahydrocannabinol and their optical isomers,
13 excluding dronabinol in sesame oil and encapsulated in a soft
14 gelatin capsule in a drug product approved by the federal Food
15 and Drug Administration; Delta 6 cis or trans tetrahydrocannabinol
16 and their optical isomers; and Delta 3,4 cis or trans
17 tetrahydrocannabinol and its optical isomers. Since nomenclature
18 of these substances is not internationally standardized, compounds
19 of these structures shall be included regardless of the numerical
20 designation of atomic positions covered;

21 (16) 3,4-methylenedioxy amphetamine;

22 (17) 5-methoxy-3,4-methylenedioxy-amphetamine;

23 (18) 3,4,5-trimethoxy amphetamine;

24 (19) N-ethyl-3-piperidyl benzilate;

25 (20) N-methyl-3-piperidyl benzilate;

26 (21) Thiophene analog of phencyclidine. Trade
27 and other names shall include, but are not limited to:

1 1-(1-(2-thienyl)-cyclohexyl)-piperidine; 2-thienyl analog of
2 phencyclidine; TCP; and TCP;
3 (22) 2,5-dimethoxyamphetamine. Trade and
4 other names shall include, but are not limited to:
5 2,5-dimethoxy-alpha-methylphenethylamine; and 2,5-DMA;
6 (23) Hashish or concentrated cannabis;
7 (24) Parahexyl. Trade and other
8 names shall include, but are not limited to:
9 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo(b,d)pyran;
10 and Synhexyl;
11 (25) Ethylamine analog of phencyclidine. Trade
12 and other names shall include, but are not limited to:
13 N-ethyl-1-phenylcyclohexylamine; (1-phenylcyclohexyl)ethylamine;
14 N-(1-phenylcyclohexyl)ethylamine; cyclohexamine; and PCE;
15 (26) Pyrrolidine analog of phencyclidine. Trade
16 and other names shall include, but are not limited to:
17 1-(1-phenylcyclohexyl)-pyrrolidine; PCPy; and PHP;
18 (27) 3,4-methylenedioxymethamphetamine (MDMA), its
19 optical, positional, and geometric isomers, salts, and salts of
20 isomers;
21 (28) 4-Bromo-2,5-dimethoxyphenethylamine. Some trade
22 or other names: 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane;
23 alpha-desmethyl DOB; 2C-B; and Nexus;
24 (29) Alpha-ethyltryptamine. Some trade or other
25 names: etryptamine; Monase; alpha-ethyl-1H-indole-3-ethanamine;
26 3-(2-aminobutyl) indole; alpha-ET; and AET;
27 (30) 2,5-dimethoxy-4-ethylamphet-amine; and DOET;

1 (31) 1-(1-(2-thienyl)cyclohexyl)pyrrolidine; and TCPy;

2 (32) Alpha-methyltryptamine, which is also known as AMT;

3 (33) 5-Methoxy-N,N-diisopropyltryptamine, which is also
4 known as 5-MeO-DIPT;

5 (34) Salvia divinorum or Salvinorin A. Salvia divinorum
6 or Salvinorin A includes all parts of the plant presently
7 classified botanically as Salvia divinorum, whether growing or not,
8 the seeds thereof, any extract from any part of such plant, and
9 every compound, manufacture, derivative, mixture, or preparation of
10 such plant, its seeds, or its extracts, including salts, isomers,
11 and salts of isomers whenever the existence of such salts, isomers,
12 and salts of isomers is possible within the specific chemical
13 designation; and

14 (35) Any material, compound, mixture, or preparation
15 containing any quantity of synthetically produced cannabinoids as
16 listed in subdivisions (i) through (viii) of this subdivision,
17 including their salts, isomers, and salts of isomers, unless
18 specifically excepted elsewhere in this section. Since nomenclature
19 of these synthetically produced cannabinoids is not internationally
20 standardized and may continually evolve, these structures or
21 compounds of these structures shall be included under this
22 subdivision, regardless of their specific numerical designation
23 of atomic positions covered, so long as it can be determined
24 through some form of scientific testing or analysis that the
25 substance contains properties that fit within one or more of the
26 following categories:

27 (i) Tetrahydrocannabinols: Meaning tetrahydrocannabinols

1 naturally contained in a plant of the genus cannabis (cannabis
2 plant), as well as synthetic equivalents of the substances
3 contained in the plant, or in the resinous extractives of
4 cannabis, sp. and/or synthetic substances, derivatives, and
5 their isomers with similar chemical structure and pharmacological
6 activity such as the following: Delta 1 cis or trans
7 tetrahydrocannabinol, and their optical isomers Delta 6 cis or
8 trans tetrahydrocannabinol, and their optical isomers Delta 3,4 cis
9 or trans tetrahydrocannabinol, and its optical isomers;

10 (ii) Naphthoylindoles: Any compound containing a
11 3-(1-naphthoyl)indole structure with substitution at the nitrogen
12 atom of the indole ring by a alkyl, haloalkyl, alkenyl,
13 cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl group,
14 whether or not further substituted in the indole ring to any extent
15 and whether or not substituted in the naphthyl ring to any extent;

16 (iii) Naphthylmethylinindoles: Any compound containing a 1
17 H-indol-3-yl-(1-naphthyl)methane structure with substitution at the
18 nitrogen atom of the indole ring by a alkyl, haloalkyl, alkenyl,
19 cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl group,
20 whether or not further substituted in the indole ring to any extent
21 and whether or not substituted in the naphthyl ring to any extent;

22 (iv) Naphthoylpyrroles: Any compound containing a
23 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen
24 atom of the pyrrole ring by a alkyl, haloalkyl, alkenyl,
25 cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl group,
26 whether or not further substituted in the pyrrole ring to any
27 extent and whether or not substituted in the naphthyl ring to any

1 extent;

2 (v) Naphthylideneindenes: Any compound containing
3 a naphthylideneindene structure with substitution at the
4 3-position of the indene ring by a alkyl, haloalkyl, alkenyl,
5 cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl group,
6 whether or not further substituted in the indene ring to any extent
7 and whether or not substituted in the naphthyl ring to any extent;

8 (vi) Phenylacetylindoles: Any compound containing a
9 3-phenylacetylindole structure with substitution at the nitrogen
10 atom of the indole ring by a alkyl, haloalkyl, alkenyl,
11 cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl group,
12 whether or not further substituted in the indole ring to any extent
13 and whether or not substituted in the phenyl ring to any extent;

14 (vii) Cyclohexylphenols: Any compound containing a
15 2-(3-hydroxycyclohexyl)phenol structure with substitution at the
16 5-position of the phenolic ring by a alkyl, haloalkyl, alkenyl,
17 cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl group,
18 whether or not substituted in the cyclohexyl ring to any extent;
19 and

20 (viii) Benzoylindoles: Any compound containing a
21 3-(benzoyl)indole structure with substitution at the nitrogen
22 atom of the indole ring by a alkyl, haloalkyl, alkenyl,
23 cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl group,
24 whether or not further substituted in the indole ring to any extent
25 and whether or not substituted in the phenyl ring to any extent;

26 and-

27 (36) (A) Any substance containing any quantity of the

1 following materials, compounds, mixtures, or structures:

2 (i) 3,4-methylenedioxy methcathinone, or bk-MDMA, or
3 methylone;

4 (ii) 3,4-methylenedioxy pyrovalerone, or MDPV;

5 (iii) 4-methylmethcathinone, or 4-MMC, or mephedrone;

6 (iv) 4-methoxymethcathinone, or bk-PMMA, or PMMC, or
7 methedrone;

8 (v) Fluoromethcathinone, or FMC;

9 (vi) Naphthylpyrovalerone, or naphyrone; or

10 (vii) Beta-keto-N-methylbenzodioxolylpropylamine; or

11 (B) Unless listed in another schedule, any substance
12 which contains any quantity of any material, compound, mixture,
13 or structure, other than bupropion, that is structurally derived
14 by any means from 2-aminopropan-1-one by substitution at the
15 1-position with either phenyl, naphthyl, or thiophene ring systems,
16 whether or not the compound is further modified in any of the
17 following ways:

18 (i) Substitution in the ring system to any extent
19 with alkyl, alkoxy, alkylendioxy, haloalkyl, hydroxyl, or halide
20 substituents, whether or not further substituted in the ring system
21 by one or more other univalent substituents;

22 (ii) Substitution at the 3-position with an acyclic alkyl
23 substituent; or

24 (iii) Substitution at the 2-amino nitrogen atom with
25 alkyl or dialkyl groups, or by inclusion of the 2-amino nitrogen
26 atom in a cyclic structure.

27 (d) Unless specifically excepted or unless listed in

1 another schedule, any material, compound, mixture, or preparation
2 which contains any quantity of the following substances having
3 a depressant effect on the central nervous system, including its
4 salts, isomers, and salts of isomers whenever the existence of
5 such salts, isomers, and salts of isomers is possible within the
6 specific chemical designation:

- 7 (1) Mecloqualone;
- 8 (2) Methaqualone; and
- 9 (3) Gamma-Hydroxybutyric Acid. Some other names include:
10 GHB; Gamma-hydroxybutyrate; 4-Hydroxybutyrate; 4-Hydroxybutanoic
11 Acid; Sodium Oxybate; and Sodium Oxybutyrate.

12 (e) Unless specifically excepted or unless listed in
13 another schedule, any material, compound, mixture, or preparation
14 which contains any quantity of the following substances having
15 a stimulant effect on the central nervous system, including its
16 salts, isomers, and salts of isomers:

- 17 (1) Fenethylamine;
- 18 (2) N-ethylamphetamine;
- 19 (3) Aminorex; aminoxaphen; 2-amino-5-phenyl-2-oxazoline;
20 or 4,5-dihydro-5-phenyl-2-oxazolamine;
- 21 (4) Cathinone; 2-amino-1-phenyl-1-propanone;
22 alpha-aminopropiophenone; 2-aminopropiophenone; and norephedrine;
- 23 (5) Methcathinone, its salts, optical isomers,
24 and salts of optical isomers. Some other names:
25 2-(methylamino)-propionophenone; alpha-(methylamino)propionophenone;
26 2-(methylamino)-1-phenylpropan-1-one;
27 alpha-N-methylaminopropiophenone; methylcathinone;

1 monomethylpropion; ephedrone; N-methylcathinone; AL-464; AL-422;
2 AL-463; and UR1432;

3 (6) (+/-) cis-4-methylaminorex; and
4 (+/-) cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine;

5 (7) N,N-dimethylamphetamine;
6 N,N-alpha-trimethyl-benzeneethanamine; and
7 N,N-alpha-trimethylphenethylamine; and

8 (8) Benzylpiperazine, 1-benzylpiperazine.

9 (f) Any controlled substance analogue to the extent
10 intended for human consumption.

11 Schedule II

12 (a) Any of the following substances except those narcotic
13 drugs listed in other schedules whether produced directly or
14 indirectly by extraction from substances of vegetable origin,
15 independently by means of chemical synthesis, or by combination of
16 extraction and chemical synthesis:

17 (1) Opium and opiate, and any salt, compound, derivative,
18 or preparation of opium or opiate, excluding apomorphine,
19 buprenorphine, thebaine-derived butorphanol, dextrorphan,
20 nalbuphine, nalmefene, naloxone, and naltrexone and their
21 salts, but including the following:

22 (i) Raw opium;

23 (ii) Opium extracts;

24 (iii) Opium fluid;

25 (iv) Powdered opium;

26 (v) Granulated opium;

27 (vi) Tincture of opium;

- 1 (vii) Codeine;
- 2 (viii) Ethylmorphine;
- 3 (ix) Etorphine hydrochloride;
- 4 (x) Hydrocodone;
- 5 (xi) Hydromorphone;
- 6 (xii) Metopon;
- 7 (xiii) Morphine;
- 8 (xiv) Oxycodone;
- 9 (xv) Oxymorphone;
- 10 (xvi) Oripavine;
- 11 (xvii) Thebaine; and
- 12 (xviii) Dihydroetorphine;
- 13 (2) Any salt, compound, derivative, or preparation
- 14 thereof which is chemically equivalent to or identical with any of
- 15 the substances referred to in subdivision (1) of this subdivision,
- 16 except that these substances shall not include the isoquinoline
- 17 alkaloids of opium;
- 18 (3) Opium poppy and poppy straw;
- 19 (4) Coca leaves and any salt, compound, derivative, or
- 20 preparation of coca leaves, and any salt, compound, derivative,
- 21 or preparation thereof which is chemically equivalent to or
- 22 identical with any of these substances, including cocaine and
- 23 its salts, optical isomers, and salts of optical isomers, except
- 24 that the substances shall not include decocainized coca leaves or
- 25 extractions which do not contain cocaine or ecgonine; and
- 26 (5) Concentrate of poppy straw, the crude extract of
- 27 poppy straw in either liquid, solid, or powder form which contains

1 the phenanthrene alkaloids of the opium poppy.

2 (b) Unless specifically excepted or unless in another
3 schedule any of the following opiates, including their isomers,
4 esters, ethers, salts, and salts of their isomers, esters, and
5 ethers whenever the existence of such isomers, esters, ethers,
6 and salts is possible within the specific chemical designation,
7 dextrorphan excepted:

- 8 (1) Alphaprodine;
- 9 (2) Anileridine;
- 10 (3) Bezitramide;
- 11 (4) Diphenoxylate;
- 12 (5) Fentanyl;
- 13 (6) Isomethadone;
- 14 (7) Levomethorphan;
- 15 (8) Levorphanol;
- 16 (9) Metazocine;
- 17 (10) Methadone;
- 18 (11) Methadone-intermediate,
19 4-cyano-2-dimethylamino-4,4-diphenyl butane;
- 20 (12) Moramide-intermediate,
21 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic acid;
- 22 (13) Pethidine or meperidine;
- 23 (14) Pethidine-Intermediate-A,
24 4-cyano-1-methyl-4-phenylpiperidine;
- 25 (15) Pethidine-Intermediate-B,
26 ethyl-4-phenylpiperidine-4-carboxylate;
- 27 (16) Pethidine-Intermediate-C,

1 1-methyl-4-phenylpiperidine-4-carboxylic acid;

2 (17) Phenazocine;

3 (18) Piminodine;

4 (19) Racemethorphan;

5 (20) Racemorphan;

6 (21) Dihydrocodeine;

7 (22) Bulk Propoxyphene in nondosage forms;

8 (23) Sufentanil;

9 (24) Alfentanil;

10 (25) Levo-alpha-acetylmethadol which is also known as

11 levo-alpha-acetylmethadol, levomethadyl acetate, and LAAM;

12 (26) Carfentanil;

13 (27) Remifentanil; and

14 (28) Tapentadol.

15 (c) Any material, compound, mixture, or preparation
16 which contains any quantity of the following substances having
17 a potential for abuse associated with a stimulant effect on the
18 central nervous system:

19 (1) Amphetamine, its salts, optical isomers, and salts of
20 its optical isomers;

21 (2) Phenmetrazine and its salts;

22 (3) Methamphetamine, its salts, isomers, and salts of its
23 isomers; and

24 (4) Methylphenidate.

25 (d) Any material, compound, mixture, or preparation
26 which contains any quantity of the following substances having
27 a potential for abuse associated with a depressant effect on the

1 central nervous system, including their salts, isomers, and salts
2 of isomers whenever the existence of such salts, isomers, and salts
3 of isomers is possible within the specific chemical designations:

- 4 (1) Amobarbital;
- 5 (2) Secobarbital;
- 6 (3) Pentobarbital;
- 7 (4) Phencyclidine; and
- 8 (5) Glutethimide.

9 (e) Hallucinogenic substances known as:

- 10 (1) Nabilone. Another name for
11 nabilone: (+/-)-trans-3-(1,1-dimethylheptyl)-
12 6,6a,7,8,10,10a-Hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo(b,d)pyran-9-one.

13 (f) Unless specifically excepted or unless listed in
14 another schedule, any material, compound, mixture, or preparation
15 which contains any quantity of the following substances:

- 16 (1) Immediate precursor to amphetamine and
17 methamphetamine: Phenylacetone. Trade and other names shall
18 include, but are not limited to: Phenyl-2-propanone; P2P; benzyl
19 methyl ketone; and methyl benzyl ketone; or

20 (2) Immediate precursors to phencyclidine, PCP:

- 21 (i) 1-phenylcyclohexylamine; or
- 22 (ii) 1-piperidinocyclohexanecarbonitrile, PCC.

23 Schedule III

24 (a) Any material, compound, mixture, or preparation
25 which contains any quantity of the following substances having
26 a potential for abuse associated with a stimulant effect on the
27 central nervous system, including their salts, isomers, whether

1 optical, position, or geometric, and salts of such isomers whenever
2 the existence of such salts, isomers, and salts of isomers is
3 possible within the specific chemical designation:

- 4 (1) Benzphetamine;
- 5 (2) Chlorphentermine;
- 6 (3) Clortermine; and
- 7 (4) Phendimetrazine.

8 (b) Any material, compound, mixture, or preparation
9 which contains any quantity of the following substances having
10 a potential for abuse associated with a depressant effect on the
11 central nervous system:

12 (1) Any substance which contains any quantity of a
13 derivative of barbituric acid or any salt of a derivative of
14 barbituric acid, except those substances which are specifically
15 listed in other schedules of this section;

- 16 (2) Chlorhexadol;
- 17 (3) Lysergic acid;
- 18 (4) Lysergic acid amide;
- 19 (5) Methyprylon;
- 20 (6) Sulfondiethylmethane;
- 21 (7) Sulfonethylmethane;
- 22 (8) Sulfonmethane;
- 23 (9) Nalorphine;

24 (10) Any compound, mixture, or preparation containing
25 amobarbital, secobarbital, pentobarbital, or any salt thereof and
26 one or more other active medicinal ingredients which are not listed
27 in any schedule;

1 (11) Any suppository dosage form containing amobarbital,
2 secobarbital, pentobarbital, or any salt of any of these drugs and
3 approved by the Food and Drug Administration for marketing only as
4 a suppository;

5 (12) Any drug product containing gamma-hydroxybutyric
6 acid, including its salts, isomers, and salts of isomers, for which
7 an application is approved under section 505 of the Federal Food,
8 Drug, and Cosmetic Act, 21 U.S.C. 355, as such section existed on
9 July 20, 2002;

10 (13) Ketamine, its salts, isomers, and
11 salts of isomers. Some other names for ketamine:
12 (+/-)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone; and

13 (14) Tiletamine and zolazepam or any salt thereof.
14 Trade or other names for a tiletamine-zolazepam combination
15 product shall include, but are not limited to: telazol. Trade
16 or other names for tiletamine shall include, but are not
17 limited to: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone. Trade or
18 other names for zolazepam shall include, but are not limited
19 to: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-(3,4-e)
20 (1,4)-diazepin-7(1H)-one, and flupyrzapon.

21 (c) Unless specifically excepted or unless listed in
22 another schedule:

23 (1) Any material, compound, mixture, or preparation
24 containing limited quantities of any of the following narcotic
25 drugs, or any salts calculated as the free anhydrous base or
26 alkaloid, in limited quantities as set forth below:

27 (i) Not more than one and eight-tenths grams of codeine

1 per one hundred milliliters or not more than ninety milligrams per
2 dosage unit, with an equal or greater quantity of an isoquinoline
3 alkaloid of opium;

4 (ii) Not more than one and eight-tenths grams of codeine
5 per one hundred milliliters or not more than ninety milligrams per
6 dosage unit, with one or more active, nonnarcotic ingredients in
7 recognized therapeutic amounts;

8 (iii) Not more than three hundred milligrams of
9 dihydrocodeinone which is also known as hydrocodone per one hundred
10 milliliters or not more than fifteen milligrams per dosage unit,
11 with a fourfold or greater quantity of an isoquinoline alkaloid of
12 opium;

13 (iv) Not more than three hundred milligrams of
14 dihydrocodeinone which is also known as hydrocodone per one hundred
15 milliliters or not more than fifteen milligrams per dosage unit,
16 with one or more active, nonnarcotic ingredients in recognized
17 therapeutic amounts;

18 (v) Not more than one and eight-tenths grams of
19 dihydrocodeine per one hundred milliliters or not more than ninety
20 milligrams per dosage unit, with one or more active, nonnarcotic
21 ingredients in recognized therapeutic amounts;

22 (vi) Not more than three hundred milligrams of
23 ethylmorphine per one hundred milliliters or not more than fifteen
24 milligrams per dosage unit, with one or more active, nonnarcotic
25 ingredients in recognized therapeutic amounts;

26 (vii) Not more than five hundred milligrams of opium per
27 one hundred milliliters or per one hundred grams, or not more than

1 twenty-five milligrams per dosage unit, with one or more active,
2 nonnarcotic ingredients in recognized therapeutic amounts; and

3 (viii) Not more than fifty milligrams of morphine per
4 one hundred milliliters or per one hundred grams with one or more
5 active, nonnarcotic ingredients in recognized therapeutic amounts;
6 and

7 (2) Any material, compound, mixture, or preparation
8 containing any of the following narcotic drug or its salts, as
9 set forth below:

10 (i) Buprenorphine.

11 (d) Unless contained on the administration's list of
12 exempt anabolic steroids as the list existed on June 1, 2007,
13 any anabolic steroid, which shall include any material, compound,
14 mixture, or preparation containing any quantity of the following
15 substances, including its salts, isomers, and salts of isomers
16 whenever the existence of such salts of isomers is possible within
17 the specific chemical designation:

18 (1) Boldenone;

19 (2) Boldione;

20 (3) Chlorotestosterone (4-chlorotestosterone);

21 (4) Clostebol;

22 (5) Dehydrochloromethyltestosterone;

23 (6) Desoxymethyltestosterone;

24 (7) Dihydrotestosterone (4-dihydrotestosterone);

25 (8) Drostanolone;

26 (9) Ethylestrenol;

27 (10) Fluoxymesterone;

- 1 (11) Formebolone (formebolone);
- 2 (12) Mesterolone;
- 3 (13) Methandienone;
- 4 (14) Methandranone;
- 5 (15) Methandriol;
- 6 (16) Methandrostenolone;
- 7 (17) Methenolone;
- 8 (18) Methyltestosterone;
- 9 (19) Mibolerone;
- 10 (20) Nandrolone;
- 11 (21) Norethandrolone;
- 12 (22) Oxandrolone;
- 13 (23) Oxymesterone;
- 14 (24) Oxymetholone;
- 15 (25) Stanolone;
- 16 (26) Stanozolol;
- 17 (27) Testolactone;
- 18 (28) Testosterone;
- 19 (29) Trenbolone;
- 20 (30) 19-nor-4,9(10)-androstadienedione; and
- 21 (31) Any salt, ester, or ether of a drug or substance
- 22 described or listed in this subdivision if the salt, ester, or
- 23 ether promotes muscle growth.

24 (e) Hallucinogenic substances known as:

- 25 (1) Dronabinol, synthetic, in sesame oil and encapsulated
- 26 in a soft gelatin capsule in a Food and Drug Administration
- 27 approved drug product. Some other names for dronabinol are

1 (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo
2 (b,d)pyran-1-ol or (-)-delta-9-(trans)-tetrahydrocannabinol.

3 Schedule IV

4 (a) Any material, compound, mixture, or preparation which
5 contains any quantity of the following substances, including their
6 salts, isomers, and salts of isomers whenever the existence of
7 such salts, isomers, and salts of isomers is possible within the
8 specific chemical designation:

- 9 (1) Barbital;
- 10 (2) Chloral betaine;
- 11 (3) Chloral hydrate;
- 12 (4) Chlordiazepoxide, but not including librax
13 (chlordiazepoxide hydrochloride and clindinium bromide) or menrium
14 (chlordiazepoxide and water soluble esterified estrogens);
- 15 (5) Clonazepam;
- 16 (6) Clorazepate;
- 17 (7) Diazepam;
- 18 (8) Ethchlorvynol;
- 19 (9) Ethinamate;
- 20 (10) Flurazepam;
- 21 (11) Mebutamate;
- 22 (12) Meprobamate;
- 23 (13) Methohexital;
- 24 (14) Methylphenobarbital;
- 25 (15) Oxazepam;
- 26 (16) Paraldehyde;
- 27 (17) Petrichloral;

- 1 (18) Phenobarbital;
- 2 (19) Prazepam;
- 3 (20) Alprazolam;
- 4 (21) Bromazepam;
- 5 (22) Camazepam;
- 6 (23) Clobazam;
- 7 (24) Clotiazepam;
- 8 (25) Cloxazolam;
- 9 (26) Delorazepam;
- 10 (27) Estazolam;
- 11 (28) Ethyl loflazepate;
- 12 (29) Fludiazepam;
- 13 (30) Flunitrazepam;
- 14 (31) Halazepam;
- 15 (32) Haloxazolam;
- 16 (33) Ketazolam;
- 17 (34) Loprazolam;
- 18 (35) Lorazepam;
- 19 (36) Lormetazepam;
- 20 (37) Medazepam;
- 21 (38) Nimetazepam;
- 22 (39) Nitrazepam;
- 23 (40) Nordiazepam;
- 24 (41) Oxazolam;
- 25 (42) Pinazepam;
- 26 (43) Temazepam;
- 27 (44) Tetrazepam;

- 1 (45) Triazolam;
- 2 (46) Midazolam;
- 3 (47) Quazepam;
- 4 (48) Zolpidem;
- 5 (49) Dichloralphenazone; and
- 6 (50) Zaleplon.

7 (b) Any material, compound, mixture, or preparation which
8 contains any quantity of the following substance, including its
9 salts, isomers, whether optical, position, or geometric, and salts
10 of such isomers, whenever the existence of such salts, isomers, and
11 salts of isomers is possible: Fenfluramine.

12 (c) Unless specifically excepted or unless listed in
13 another schedule, any material, compound, mixture, or preparation
14 which contains any quantity of the following substances having a
15 stimulant effect on the central nervous system, including their
16 salts, isomers, whether optical, position, or geometric, and salts
17 of such isomers whenever the existence of such salts, isomers,
18 and salts of isomers is possible within the specific chemical
19 designation:

- 20 (1) Diethylpropion;
- 21 (2) Phentermine;
- 22 (3) Pemoline, including organometallic complexes and
23 chelates thereof;
- 24 (4) Mazindol;
- 25 (5) Pipradrol;
- 26 (6) SPA, ((-)-1-dimethylamino- 1,2-diphenylethane);
- 27 (7) Cathine. Another name for cathine is

1 ((+)-norpseudoephedrine);

2 (8) Fencamfamin;

3 (9) Fenproporex;

4 (10) Mefenorex;

5 (11) Modafinil; and

6 (12) Sibutramine.

7 (d) Unless specifically excepted or unless listed in
8 another schedule, any material, compound, mixture, or preparation
9 which contains any quantity of the following narcotic drugs, or
10 their salts or isomers calculated as the free anhydrous base or
11 alkaloid, in limited quantities as set forth below:

12 (1) Propoxyphene in manufactured dosage forms; and

13 (2) Not more than one milligram of difenoxin and not less
14 than twenty-five micrograms of atropine sulfate per dosage unit.

15 (e) Unless specifically excepted or unless listed in
16 another schedule, any material, compound, mixture, or preparation
17 which contains any quantity of the following substance, including
18 its salts: Pentazocine.

19 (f) Unless specifically excepted or unless listed in
20 another schedule, any material, compound, mixture, or preparation
21 which contains any quantity of the following substance, including
22 its salts, isomers, and salts of such isomers: Butorphanol.

23 (g) Unless specifically excepted or unless listed in
24 another schedule, any material, compound, mixture, or preparation
25 which contains any quantity of the following substance, including
26 its salts, isomers, and salts of such isomers: Carisoprodol.

27 ~~(g)(1)~~ (h)(1) Unless specifically excepted or unless

1 listed in another schedule, any material, compound, mixture, or
2 preparation which contains any quantity of the following substance,
3 including its salts, optical isomers, and salts of such optical
4 isomers: Ephedrine.

5 (2) The following drug products containing ephedrine, its
6 salts, optical isomers, and salts of such optical isomers, are
7 excepted from subdivision ~~(g)(1)~~ (h)(1) of Schedule IV if they
8 (A) are stored behind a counter, in an area not accessible to
9 customers, or in a locked case so that a customer needs assistance
10 from an employee to access the drug product; (B) are sold by a
11 person, eighteen years of age or older, in the course of his or her
12 employment to a customer eighteen years of age or older with the
13 following restrictions: No customer shall be allowed to purchase,
14 receive, or otherwise acquire more than three and six-tenths grams
15 of ephedrine base during a twenty-four-hour period; no customer
16 shall purchase, receive, or otherwise acquire more than nine grams
17 of ephedrine base during a thirty-day period; and the customer
18 shall display a valid driver's or operator's license, a Nebraska
19 state identification card, a military identification card, an alien
20 registration card, or a passport as proof of identification; (C)
21 are labeled and marketed in a manner consistent with the pertinent
22 OTC Tentative Final or Final Monograph; (D) are manufactured and
23 distributed for legitimate medicinal use in a manner that reduces
24 or eliminates the likelihood of abuse; and (E) are not marketed,
25 advertised, or represented in any manner for the indication of
26 stimulation, mental alertness, euphoria, ecstasy, a buzz or high,
27 heightened sexual performance, or increased muscle mass:

1 (i) Primatene Tablets; and

2 (ii) Bronkaid Dual Action Caplets, ~~and~~

3 ~~(iii) Paze Hemorrhoidal Ointment.~~

4 Schedule V

5 (a) Any compound, mixture, or preparation containing any
6 of the following limited quantities of narcotic drugs or salts
7 calculated as the free anhydrous base or alkaloid, which shall
8 include one or more nonnarcotic active medicinal ingredients in
9 sufficient proportion to confer upon the compound, mixture, or
10 preparation valuable medicinal qualities other than those possessed
11 by the narcotic drug alone:

12 (1) Not more than two hundred milligrams of codeine per
13 one hundred milliliters or per one hundred grams;

14 (2) Not more than one hundred milligrams of
15 dihydrocodeine per one hundred milliliters or per one hundred
16 grams;

17 (3) Not more than one hundred milligrams of ethylmorphine
18 per one hundred milliliters or per one hundred grams;

19 (4) Not more than two and five-tenths milligrams of
20 diphenoxylate and not less than twenty-five micrograms of atropine
21 sulfate per dosage unit;

22 (5) Not more than one hundred milligrams of opium per one
23 hundred milliliters or per one hundred grams; and

24 (6) Not more than five-tenths milligram of difenoxin and
25 not less than twenty-five micrograms of atropine sulfate per dosage
26 unit.

27 (b) Unless specifically exempted or excluded or unless

1 listed in another schedule, any material, compound, mixture, or
2 preparation which contains any quantity of the following substances
3 having a stimulant effect on the central nervous system, including
4 its salts, isomers, and salts of isomers: Pyrovalerone.

5 (c) Unless specifically exempted or excluded or unless
6 listed in another schedule, any material, compound, mixture, or
7 preparation which contains any quantity of the following substances
8 having a depressant effect on the central nervous system, including
9 its salts, isomers, and salts of isomers:

10 (1) Ezogabine
11 [N-[2-amino-4-(4-fluorobenzylamino)-phenyl]-carbamic
12 acid ethyl ester];

13 (2) Lacosamide
14 [(R)-2-acetoamido-N-benzyl-3-methoxy-propionamide]; and

15 (3) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic
16 acid].

17 Sec. 2. Original section 28-405, Revised Statutes
18 Supplement, 2011, is repealed.

19 Sec. 3. Since an emergency exists, this act takes effect
20 when passed and approved according to law.